Evidence map›Paper›PMID 39841423›Full record

ReviewCancer journal (Sudbury, Mass.)

Recent Advancements and Future Perspectives on Molecular Biomarkers in Adult Lower-Grade Gliomas.

Jessica L Fleming, Arnab Chakravarti

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jessica L FlemingFrom the Department of Radiation Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH.
Arnab Chakravarti

Funding

OSU as Network Lead Academic Participating Site for the NCI NCTNU10CA180850 · NCI · OHIO STATE UNIVERSITY · PI BLUM, KRISTIE A, CHAKRAVARTI, ARNAB · 2014 to 2018
$6.8M
Signal Transduction Pathways in GlioblastomaR01CA108633 · NCI · OHIO STATE UNIVERSITY · PI CHAKRAVARTI, ARNAB · 2005 to 2009
$2.3M
TOWARDS A REFINED MOLECULAR RECURSIVE PARTITIONING ANALYSIS MODEL FOR GLIOBLASTOMRC2CA148190 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI ALDAPE, KENNETH D, CHAKRAVARTI, ARNAB · 2009 to 2010
$2.1M
Therapeutic Exploitation of Mutant BRAF for AstrocytomaR01CA169368 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HOUGHTON, PETER J · 2013 to 2017
$1.6M
NCI NIH HHS R01 CA108633NCI NIH HHS R01 CA169368NCI NIH HHS RC2 CA148190NCI NIH HHS U10 CA180850
6 · The paper itself

Abstract

abstractThere has been a significant paradigm shift in the clinical management of lower-grade glioma patients given the recent updates to the 2021 World Health Organization classification along with long-term results from randomized phase III clinical trials. As a result, we are now better able to diagnose and assign patients to the most appropriate treatment course. This review provides a comprehensive summary of the most robust and reliable molecular biomarkers for adult lower-grade gliomas and discusses current challenges facing this patient population that future correlative biology studies combined with advancements in technologies could help overcome.

Indexed as

Biomarkers, TumorBrain NeoplasmsGliomaAdultHumansNeoplasm GradingBiomarkers, Tumor

Identifiers

PMID39841423
PMCPMC12857766

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.